- Vouliez-vous dire
- cervical epithelial neoplasms
Résultats de la recherche - 16 results
Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
1.04) for cervical intraepithelial neoplasia grade 2 or worse (CIN2 +) and 1.01 (95% CI, 0.97 to 1.06) for CIN3 + and relative specificity of 1.02 (95% CI, 1.00 to 1.03) for a CIN grade of ≤1. The ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
Alphapapillomavirus Cervical Intraepithelial Neoplasia Cervix Uteri Diagnostic Tests, Routine DNA, Viral Early Detection of Cancer Female Genotyping Techniques Humans Papillomavirus Infections Uterine Cervical ...
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
the standard comparator tests to detect high-grade cervical intraepithelial neoplasia or cancer in primary screening. The cobas 4800 HPV test and Abbott RealTime High Risk HPV test were consistently ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
Microbiol, Volume 52, Issue 11, p.3996-4002 (2014) Keywords: Adult Cervical Intraepithelial Neoplasia Cervix Uteri Early Detection of Cancer Female Humans middle aged Molecular Diagnostic Techniques ...
Human papillomavirus-based triage of women showing a cervical cytology result of borderline or mild dyskaryosis.
Publication Type: Peer reviewed scientific article Authors: M. Arbyn; Martin-Hirsch, P; Wentzensen, N Source: BJOG, Volume 117, Issue 6, p.641-4 (2010) Keywords: Adult Cervical Intraepithelial ...
The challenges of organising cervical screening programmes in the 15 old member states of the European Union.
J Cancer, Volume 45, Issue 15, p.2671-8 (2009) Keywords: Adult Aged Cervical Intraepithelial Neoplasia Cost-Benefit Analysis Europe European Union Female Forecasting Humans Mass Screening middle aged ...